Cranbury-based PMV Pharmaceuticals Inc., a drug development company for the treatment of cancer, announced it has appointed Dr. Salim Yazji as its new chief medical officer.
Prior to PMV Pharma, Yazji was executive vice president and chief medical officer at Calimmune Inc.
“Salim’s depth of experience and proven leadership in shepherding innovative products from pre-clinical development through product approval will be critical as we advance towards the clinic,” said David Mack, CEO and president of PMV Pharma. “We are delighted to welcome Salim to our team. Salim’s rich experience in leading oncology clinical trials and drug development will help define our clinical and regulatory strategies for our multiple programs.”
Salim will be based in the Boston area where the company’s clinical and regulatory operations are.
“PMV Pharma is at the forefront of developing transformational products in oncology,” Yazji said. “I am thrilled to join the PMV Pharma team at this important juncture with the opportunity to work alongside a highly skilled scientific team, key opinion leaders and management team.”
Prior to joining Calimmune, he was vice president and global therapeutic head at Baxalta, Inc. Before that, he was vice president and therapeutic area head of oncology at Baxter. He’s also held leadership roles at Novartis Pharmaceuticals, Exelixis Inc., PDL BioPharma Inc. and Johnson & Johnson.
